Op‐7 Therapeutic Effects of Domperidone on Abdominal Pain‐predominant Functional Gastrointestinal Disorders

Abstract

Background: Impaired gut barrier function has been reported in some functional gastrointestinal (GI) disorders. Evidences suggest that gut microbiota affects GI motility in particular Lactobacillus species elicits anti-inflammatory activity and exerts protective effects on damage induced by pathogen Gram negative-derived lipopolysaccharide (LPS). LPS produced an oxidative imbalance in human colonic smooth muscle cells (SMC) that persists after LPS-washout and contributes to SMC morphofunctional alterations. The aim was to evaluate if supernatants harvested from LGG cultures protect SMC from LPS-induced myogenic damage. Methods: L. rhamnosus GG (ATCC 53103 strain) was grown in MRS medium and samples were collected from bacterial cultures in middle exponential phase, in early, in middle and late stationary phase (overnight). Supernatants were recovered, filtered and stored at -20 8C. Highly pure human SMC culture was then exposed for 24 h to highly purified LPS (1 mg/ml) of E. coli (O111:B4) in the absence and presence of the supernatants. Their effects were evaluated on LPS-induced SMC morphofunctional alterations and pro-inflammatory IL-6 production. Data are expressed as mean AE SE (P < 0.05 significant). Results: LPS induced persistent significant 20.7% AE 1.2 cell shortening and 35.2% AE 2.6 decrease in contraction of human colonic SMC. These alterations were paralleled to a 238.5% AE 82.5% increase in IL-6 production. These effects disappeared in the presence of LGG-supernatants, following a progression related to LGG growth curve phases. Supernatants collected in the middle exponential phase already significantly partially restored LPS-induced cell shortening by 43.4% AE 10.2% and IL-6 increase by 47.6% AE 13.1%, but had no effect on LPS-induced inhibition of contraction. Supernatants collected later, in the early and middle stationary phase, further counteract LPS-induced damage, including inhibition of contraction. Maximal protective effects were observed with supernatants of the late stationary phase where LPS-induced cell shortening was reversed by 86% AE 4.7%, inhibition of contraction by 98.2% AE 1.8%, and IL-6 basal production by 91.3% AE 0.6%. Conclusions: LGG-secreted products are substances/byproducts able to directly protect human SMC from LPS-induced myogenic damage. Novel insights are then provided about the possibility that LGG-derived products could reduce the risk of progression to a post-infective motor disorder.

Recurrent Abdominal Pain in Children

“…Single studies assessed the effectiveness of 8 different pharmacological agents compared to usual care or placebo: the anti-muscarinic drug trimebutine (53), the 5-HT 4 (5-hydroxytryptamine) agonist tegaserod (54), the antihistamine cyproheptadine (55), the serotonin agonist pizotifen (56), the selective serotonin reuptake inhibitor citalopram (57), the hormone melatonin (58), the dopamine receptor agonist domperidone (59), and the H2 receptor agonist famotidine (60). Four studies reported significant reductions in pain (53)(54)(55)(56), 2 reported mixed findings (59,60), and 3 no effect on pain outcomes (57,58). Small sample sizes, poor reporting, and a lack of recognised pain outcome measures meant there was insufficient evidence of effectiveness for these single studies of pharmacological intervention.…”